Q2 2025 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2025-08-14 · accession 0001415889-25-021914
$1.33B
Reported value
31
Positions
2025-06-30
Period end
The Brief · Venrock Adviser, LLC · Q2 2025
AI · grounded in 13F
Venrock Adviser, LLC established a new position in APGE valued at $368.9M. The fund also initiated new stakes in OCUL for $118.4M and METSERA INC for $106.7M. Additional new positions include ELVN at $80.8M and KALV at $76.1M. Total assets under management stand at $1.33B across 31 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $368.9M | 27.6% | 8,493,321 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $118.4M | 8.88% | 12,762,462 | Common | SOLE |
| 59267L107 | — | METSERA INC | $106.7M | 8.00% | 3,750,662 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $80.8M | 6.05% | 4,026,331 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $76.1M | 5.70% | 6,728,985 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $67.0M | 5.02% | 6,596,885 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $54.3M | 4.07% | 3,882,709 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $46.5M | 3.48% | 4,148,428 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $40.2M | 3.01% | 2,685,448 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $36.0M | 2.70% | 2,047,620 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $34.1M | 2.56% | 4,755,411 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $32.2M | 2.41% | 3,220,364 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $31.7M | 2.38% | 13,969,882 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $31.1M | 2.33% | 639,088 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $25.2M | 1.89% | 2,295,319 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $22.7M | 1.70% | 17,857,083 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $22.4M | 1.68% | 1,387,864 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $20.7M | 1.55% | 2,173,913 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $20.3M | 1.52% | 8,884,263 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $18.6M | 1.40% | 1,000,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $18.4M | 1.38% | 5,046,414 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $13.2M | 0.99% | 2,457,348 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $10.4M | 0.78% | 1,379,965 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $10.3M | 0.77% | 1,345,780 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $8.0M | 0.60% | 750,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $5.7M | 0.43% | 540,453 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $5.7M | 0.42% | 632,931 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $4.9M | 0.36% | 4,631,216 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $2.4M | 0.18% | 1,609,569 | Common | SOLE |
| G1933S101 | CASIF | CASI PHARMACEUTICALS INC | $1.2M | 0.09% | 987,259 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $567,729 | 0.04% | 98,564 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.